Open signals
2516
Active intelligence signals
Critical
468
Importance score ≥ 8
Requires action
181
Investigate or escalate
Signal intelligence
View allCritical signals
Score ≥ 8 — board-level attention
9FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
EscalateNephrology · Autoimmune Disease
9FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
InvestigateOncology · Bladder Cancer
9FDA Approves Veklury as First Treatment for COVID-19
InvestigateInfectious Disease · Antiviral
9Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
EscalateOncology · KRAS G12C NSCLC
9Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
EscalateOncology · KRAS G12C Non-Small Cell Lung Cancer
9Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma
EscalateOncology · Immune-Mobilizing T-cell Receptors
9Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
EscalateInfectious Disease · Respiratory Syncytial Virus (RSV)
9FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
EscalateImmunology · Systemic Lupus Erythematosus
9Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
EscalateNeurology · Autoimmune Disease
9Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
EscalateNeurology · Alzheimer's Disease
9FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
EscalateOncology · Prostate Cancer
9Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
EscalateOncology · ADC
9Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
EscalateOncology · NSCLC
9FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
EscalateOncology · Breast Cancer
9FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
EscalateOncology · Breast Cancer
9FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
EscalateOncology · Immunotherapy
8FDA Grants Priority Review for ABBVIE's BLA761460 (DECNUPAZ)
MonitorOncology · Monoclonal Antibody
8FDA Approves Differin Epiduo Acne Gel for Acne Treatment
MonitorDermatology · Acne
8Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease
MonitorNeurology · Alzheimer's Disease
8FDA Grants Priority Review for Datopotamab Deruxtecan Supplement
MonitorOncology · ADC
8FDA Grants Priority Review for BLA761468 (HEPCLUDEX) by Gilead Sciences
MonitorHepatology · Antiviral
8FDA Approves Supplement for Biktarvy by Gilead Sciences
MonitorInfectious Disease · HIV
8FDA Accepts Supplemental NDA for Linzess by AbbVie
MonitorGastroenterology · IBS-C
8University of Missouri-Columbia Launches Naloxone Training Initiative to Combat Opioid Overdoses
MonitorAddiction · Opioids
8FDA mandates compliance for imported Heparin Sodium with USP specifications
MonitorCardiovascular · Anticoagulant
8FDA Approves Supplement for NYVEPRIA (PEGFILGRASTIM-APGF)
MonitorOncology · Supportive Care
8FDA Approves HERCEPTIN HYLECTA Supplement Application
MonitorOncology · HER2-positive Breast Cancer
8SEPTIN9 methylation in ctDNA predicts MRD in colorectal cancer patients post-surgery
MonitorOncology · Colorectal Cancer
8Resmetirom (Rezdiffra) Approved for MASH Treatment in Adults
InvestigateHepatology · Metabolic Dysfunction-Associated Steatohepatitis
8Galectin-3+PD-L1+ CECs identified as immunosuppressive drivers in TNBC
InvestigateOncology · Breast Cancer
8FDA Approves PHESGO Supplement for Genentech's Combination Therapy
MonitorOncology · HER2-positive Breast Cancer
8FDA Grants Priority Review for Tecentriq Hybreza Supplement Application
MonitorOncology · Immunotherapy
8Otsuka's OPC-167832 Trial for Drug-Susceptible TB Shows Promise Against Standard Regimen
MonitorInfectious Disease · Tuberculosis
8Novel MOF P/ZnO Nanocomposite Shows Promise for Targeted Cancer Therapy
InvestigateOncology · Nanomedicine
8Mirati's Adagrasib Plus Pembrolizumab Trial for NSCLC Shows Promise
MonitorOncology · NSCLC
8FDA Approves First Oral PCSK9 Inhibitor Lipfendra for High Cholesterol
InvestigateCardiology · Cholesterol Management
8FDA Grants Approval for Enlicitide by Merck Sharp and Dohme
MonitorEndocrinology · Hormonal Therapy
8FDA Approves Supplemental Application for Retevmo (Selpercatinib)
MonitorOncology · RET Inhibitor
8FDA Grants Approval for Afatinib Dimaleate ANDA210750
MonitorOncology · EGFR Inhibitor
8FDA Approves REVTORPYK (GEDATOLISIB) for Celcuity Inc.
MonitorOncology · PI3K Inhibitor
8Novartis Fabhalta® (iptacopan) gains FDA approval for primary IgAN treatment
MonitorNephrology · Complement Inhibition
8Merck's LIPFENDRA Approved as First Oral PCSK9 Inhibitor for Hypercholesterolemia
InvestigateCardiology · Hypercholesterolemia
8FDA Grants Priority Review for Tecentriq Supplement Application
MonitorOncology · PD-L1 Inhibitor
8FDA Accepts BLA for IMMGOLIS (GOLIMUMAB-SLDI) by Accord Biopharma
MonitorImmunology · TNF Inhibitor
8FDA Grants Approval for Dr. Reddy's Venetoclax ANDA214733
MonitorOncology · BCL-2 Inhibitor
8FDA Approves BAXFENDY (BAXDROSTAT) by AstraZeneca
InvestigateEndocrinology · Hypertension
8FDA Grants Priority Review for ENHERTU Supplement Application
MonitorOncology · ADC
8FDA Approves TRIMBOW (NDA219622) by Chiesi
InvestigateRespiratory · Asthma/COPD
8Dietary Butyrate Enhances Anti-PD-1 Efficacy in NSCLC via Gut Microbiome Modulation
InvestigateOncology · Immunotherapy
8B. Braun Medical Recalls Spinal Anesthesia Kits Due to Bupivacaine Hydrochloride Issues
InvestigateAnesthesia · Injectable
8CCL2/TIMP1 Axis Identified as Key Driver in Glioblastoma's Immunosuppressive Microenvironment
InvestigateOncology · Glioblastoma
8Lilly to acquire AtaiBeckley to enhance treatment-resistant depression therapies
InvestigateNeuroscience · Depression
8KEYTRUDA Shows Significant PFS Improvement in dMMR Endometrial Cancer in Phase 3 Trial
MonitorOncology · PD-1 Inhibition
8FDA Approves Gallium Ga-68 Gozetotide for Diagnostic Use
MonitorOncology · Radiopharmaceutical
8Bayer's Mirena Investigated for Nonatypical Endometrial Hyperplasia Treatment
MonitorGynecology · Endometrial Hyperplasia
8Resmed Astral Ventilators Face Serious Electrical Component Failure Risk
InvestigateRespiratory · Ventilation
8FDA Grants Priority Review for LEQEMBI Supplement Application
MonitorNeurology · Alzheimer's Disease
8MHRA Strengthens Warnings for Botulinum Toxin Type A Products Due to Botulism Cases
InvestigateNeurology · Botulinum Toxin
8Updated Warnings on Botulinum Toxin Type A Products Due to Iatrogenic Botulism Risk
MonitorNeurology · Botulinum Toxin
8Phase 2 Study Shows Safety and Enhanced Immunogenicity of mRNA-1010 Influenza Vaccine
MonitorInfectious Disease · Influenza
8FDA Grants Priority Review for BEQALZI (Sonrotoclax) NDA220711
MonitorOncology · BCL-2 Inhibitor
8FDA Approves First Generics of Gilotrif (afatinib) Tablets
MonitorOncology · NSCLC
8FDA approves gedatolisib with fulvestrant for HR-positive, HER2-negative breast cancer
InvestigateOncology · Breast Cancer
8Baxter Issues Correction for Volera Positive Pressure Breathing Devices Due to Air Leakage
MonitorRespiratory · Medical Devices
8FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application
MonitorOncology · PD-1 Inhibitor
8FDA grants priority review for PADCEV supplemental application
MonitorOncology · ADC
8Tislelizumab and Disitamab-Vedotin Show Promise in Neoadjuvant Therapy for HER2-positive UTUC
MonitorOncology · HER2-positive Upper Tract Urothelial Carcinoma
8FDA grants priority review for KEYTRUDA supplemental application
MonitorOncology · PD-1 Inhibitor
8FDA Accepts Application for SARCLISA (Isatuximab-IRFC) by Sanofi
MonitorOncology · Monoclonal Antibody
8FDA Approves Selpercatinib for RET Fusion-Positive Solid Tumors
MonitorOncology · RET Fusion-Positive Tumors
8Roche's Elecsys IGRA TB Test Receives CE Mark for Tuberculosis Detection
MonitorInfectious Diseases · Tuberculosis
8FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
MonitorNephrology · Autoimmune Disease
8UCB NK Cells Enhance Anti-GD2 Therapy Efficacy in Neuroblastoma
InvestigateOncology · Neuroblastoma
8FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application
MonitorOncology · PD-1 Inhibitor
8FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals
MonitorInfectious Disease · Antibiotic
8FDA Grants Priority Review for BIZENGRI Supplement by Merus N.V.
MonitorOncology · BiTE
8FDA Grants Priority Review for OCREVUS Supplemental Application
MonitorNeurology · Multiple Sclerosis
8FDA Grants Priority Review for VYVGART HYTRULO Supplement by ARGENX
MonitorImmunology · Autoimmune Disorders
8FDA Supports Development of Psychedelic Drugs for Mental Health
InvestigateMental Health · Psychedelics
8FDA Approves First At-home Starting Dose for Leqembi in Alzheimer's Treatment
MonitorNeurology · Alzheimer's Disease
8Medtronic Recalls Harmony Delivery Catheter Due to Detachment Risk
InvestigateCardiology · Medical Device
8AstraZeneca's Dapagliflozin Approved for Heart Failure; Real-World Study Launched in Germany
MonitorCardiology · Heart Failure
8Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation
MonitorNeurology · Alzheimer's Disease
8Neladalkib (NVL-655) shows promise in Phase 3 trial for ALK-positive NSCLC
MonitorOncology · NSCLC
8AstraZeneca licenses novel EGFR inhibitor Zegfrovy for lung cancer
MonitorOncology · EGFR Inhibitor
8Roche launches first fully automated cobas HDV test for Hepatitis D diagnosis
MonitorInfectious Diseases · Hepatitis D
8Roche Launches First Fully Automated HDV Test to Enhance Diagnosis and Monitoring
MonitorInfectious Diseases · Hepatitis D
8Novel CDK7 Inhibitor 7a Shows Potent Antitumor Activity in Colorectal Cancer Models
InvestigateOncology · CDK7 Inhibition
8FDA Grants Priority Review for VYVGART Supplement Application
MonitorImmunology · IgG4-related disease
8DisCoVeRy Trial Evaluates AZD7442 for COVID-19 in Hospitalized Adults
MonitorInfectious Disease · COVID-19
8Crescent Pharma recalls Ramipril 2.5mg due to packaging error
InvestigateCardiovascular · Antihypertensive
8FDA Approves Supplemental Application for BRILINTA (Ticagrelor)
MonitorCardiology · Antiplatelet
8Gut Microbiota's Role in Colorectal Cancer: Insights for Targeted Therapies
InvestigateOncology · Colorectal Cancer
8Brentuximab vedotin shows effectiveness over standard chemotherapy in relapsed Hodgkin lymphoma
MonitorOncology · Hodgkin Lymphoma
8LYTACs: A New Strategy to Combat Cancer Drug Resistance
InvestigateOncology · Targeted Protein Degradation
8High-Dose Quadrivalent Influenza Vaccine Shows Superior Immunogenicity in Young Children
InvestigateInfectious Disease · Influenza
8Allurion Gastric Balloon Safety Update: Risks of Obstruction and Perforation
MonitorObesity · Medical Device
8FDA Approves Supplemental Application for Wegovy (Semaglutide)
InvestigateObesity · GLP-1 Agonist
8FDA Approves JAKAFI XR for Incyte Corp.
MonitorHematology · JAK Inhibitor
8Divarasib Study Targets KRAS G12C-Positive NSCLC Post-Chemoimmunotherapy
MonitorOncology · KRAS G12C-Positive Non-Small Cell Lung Cancer
8Single-cell analysis reveals immune evasion pathways in thyroid cancer metastasis
InvestigateOncology · Thyroid Cancer
8HEC116094 Shows Potent Activity as PB2 Inhibitor Against Influenza A Virus
InvestigateInfectious Disease · Influenza
8Immune Profiling in dMMR/MSI-H CRC Reveals Prognostic Insights and Immunotherapeutic Potential
InvestigateOncology · Colorectal Cancer
8FDA Grants Priority Review for TRUTAKNA (BLA761486) by Vera Therapeutics
MonitorImmunology · Monoclonal Antibody
8FDA Approves KEYTRUDA and KEYTRUDA QLEX for Muscle-Invasive Bladder Cancer
MonitorOncology · PD-1 Inhibitor and ADC
8EBV Reprograms Immune Escape in Nasopharyngeal Carcinoma, Impacting Immunotherapy Efficacy
InvestigateOncology · Nasopharyngeal Carcinoma
8FDA Accepts NDA for Vepdegestant by Arvinas Operations
MonitorOncology · Estrogen Receptor Modulator
8Merck's Sacituzumab Tirumotecan in TNBC Shows Potential in Combination with Pembrolizumab
MonitorOncology · Triple-Negative Breast Cancer
8Advancements and Challenges in HPV Vaccine Development for Cancer Treatment
InvestigateOncology · HPV-related cancers
8Identification of Bakuchiol as Potent Bacterial Neuraminidase Inhibitor from Psoralea corylifolia
InvestigateInfectious Disease · Antibacterial
8FDA Accepts BLA for Langlara by Sunshine Lake Pharma
MonitorDiabetes · Insulin
8Nanotechnology Advances in Podocyte Injury Repair for Chronic Kidney Diseases
InvestigateNephrology · Chronic Kidney Disease
8Project Orbis Aims to Accelerate Cancer Drug Approvals
MonitorOncology · Drug Development
8FDA Approves Pembrolizumab Combinations for Muscle Invasive Bladder Cancer
MonitorOncology · Bladder Cancer
8FDA Approves Isatuximab-irfc Subcutaneous Injection for Multiple Myeloma
MonitorHematology · Multiple Myeloma
8FDA Alerts on Non-Sterile BD ChloraPrep Applicators in Medline Convenience Kits
InvestigateInfection Control · Medical Devices
8POU2F2 identified as a key oncogenic and immunomodulatory factor in kidney cancer
MonitorOncology · Kidney Cancer
8Microbiota and Metabolites Influence Immunotherapy Response in Triple-Negative Breast Cancer
InvestigateOncology · Triple-Negative Breast Cancer
8Pfizer's Ibuzatrelvir Study Targets High-Risk COVID-19 Patients
MonitorInfectious Disease · COVID-19
8Biomarker-guided care improves outcomes in nulliparous pregnancies at risk for preterm birth
InvestigateObstetrics · Preterm Birth
8Novel ALA-HPO hybrids show enhanced efficacy in photodynamic therapy for superficial tumors
InvestigateOncology · Photodynamic Therapy
8Elranatamab shows robust efficacy and favorable safety in relapsed/refractory multiple myeloma
MonitorHematology · Multiple Myeloma
8MHRA Approves UK Plasma Donations for Key Medicinal Products
InvestigateHematology · Plasma-derived therapies
8FT-IR Spectroscopy Identifies Non-Invasive Biomarkers for Kidney Cancer Detection
InvestigateOncology · Kidney Cancer
8Phase 3 Trial of SHR-8068, Adebrelimab, and Bevacizumab in Hepatocellular Carcinoma
MonitorOncology · Hepatocellular Carcinoma
8Pembrolizumab Plus Enzalutamide Trial in mCRPC Shows Promise for Overall Survival
MonitorOncology · Prostate Cancer
8Epcoritamab + Lenalidomide and Rituximab Outperforms Chemoimmunotherapy in R/R Follicular Lymphoma
MonitorOncology · Follicular Lymphoma
8Lilly presents new Alzheimer's diagnostic and therapeutic data at AAIC 2026
MonitorNeurology · Alzheimer's Disease
8Phase III Trial of Tislelizumab and Lenvatinib in Unresectable Intrahepatic Cholangiocarcinoma
MonitorOncology · Intrahepatic Cholangiocarcinoma
8Fluoxetine Janus dendrimer shows potent anticancer activity against MCF-7 cells
InvestigateOncology · Dendrimer-based therapy
8FDA Approves Supplemental Application for RINVOQ LQ by AbbVie
MonitorImmunology · JAK Inhibitor
8FDA Grants Priority Review for KISQALI FEMARA Co-Packaged Product
MonitorOncology · Combination Therapy
8FDA Grants Priority Review for KISQALI Supplement by Novartis
MonitorOncology · CDK4/6 Inhibitor
8FDA Approves Supplemental Application for XELJANZ XR by Pfizer
MonitorImmunology · JAK Inhibitor
84D Flow MRI Study Aims to Improve Risk Stratification for Variceal Bleeding in Cirrhosis
MonitorHepatology · Cirrhosis
8Novel compound AG3 shows promise for targeting p53-Y220C mutation in gastric cancer
InvestigateOncology · Gastric Cancer
8Nerandomilast (Jascayd) Approved for Idiopathic and Progressive Pulmonary Fibrosis
InvestigatePulmonology · Idiopathic Pulmonary Fibrosis
8Phase I/II Trial of Iberdomide in Relapsed Neuroblastoma Shows Potential Efficacy
MonitorOncology · Neuroblastoma
8Advances in NSP13 helicase inhibitors for broad-spectrum anti-coronavirus therapy
InvestigateInfectious Disease · Coronavirus
8Advancements in Single-Cell and Spatial Transcriptomics for Pancreatic Cancer Insights
InvestigateOncology · Pancreatic Cancer
8HPV Vaccination Shows High Efficacy Against Cancer and Precancer Outcomes
InvestigateOncology · HPV-related cancers
8Sandoz Receives FDA Approval for Liraglutide ANDA212972
MonitorEndocrinology · GLP-1 Agonist
8Phase II/III Trial Evaluates Docetaxel-Cetuximab with Atezolizumab in High-Risk Head and Neck Cancer
MonitorOncology · Head and Neck Cancer
8AstraZeneca's Wainua fails primary endpoint in ATTR-CM Phase III trial
InvestigateCardiology · ATTR-CM
8Roche's Elecsys IGRA TB Test Receives CE Mark for Tuberculosis Detection
MonitorInfectious Diseases · Tuberculosis
8MHRA Launches Consultation for Earlier Licensing of Rare Disease Therapies
MonitorRare Diseases · Various
8Risk of Severe Harm from Incorrect Blood Transfusion Administration Sets
MonitorHematology · Blood Transfusion
8City of Hope Initiates Liquid Biopsy Study for Early Colorectal Cancer Detection
MonitorOncology · Colorectal Cancer
8SINGLE-AF Trial Evaluates DOACs in Intermediate Stroke Risk Atrial Fibrillation Patients
MonitorCardiology · Anticoagulation
8FDA Grants Approval for Rivaroxaban Generic by Micro Labs
MonitorCardiovascular · Anticoagulant
8UBE2C identified as a key driver in pancreatic cancer via PI3K/Akt/mTOR pathway
InvestigateOncology · Pancreatic Cancer
8FDA Approves Supplemental NDA for Pfizer's Ritlecitinib Tosylate (Litfulo)
MonitorDermatology · JAK Inhibitor
8FDA Grants Approval for PIXXOSCAN (Gadobutrol) by GE Healthcare
MonitorImaging · Contrast Agent
8FDA Approves Supplemental Application for TRUXIMA (Rituximab-ABBS)
MonitorOncology · Monoclonal Antibody
8Preclinical SNAP™-TIL therapy shows promise for broader cancer treatment efficacy
MonitorOncology · TIL Therapy
8FDA Approves Trutakna for Proteinuria in Primary IgA Nephropathy
MonitorNephrology · Immunoglobulin A Nephropathy
8Phase II Trial of Becotatug Vedotin with Tislelizumab and Lenvatinib in Advanced ESCC
MonitorOncology · Esophageal Squamous Cell Carcinoma
8Phase 1 Trial of LMP744 in Recurrent Glioblastoma Shows Potential for New Treatment
MonitorOncology · Glioblastoma
8TGFA identified as key regulator in cervical cancer progression via DSG2 interaction
InvestigateOncology · Cervical Cancer
8FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS
MonitorNeurology · Parkinson's Disease
8Novel bispecific T-cell engagers show promise against EGFR resistance in cancer
MonitorOncology · EGFR-targeted therapies
8FDA Authorizes Baricitinib and Remdesivir Combination for COVID-19 Treatment
InvestigateInfectious Disease · COVID-19
8FDA Warns of Drug Interaction Reducing Remdesivir Effectiveness in COVID-19 Treatment
InvestigateInfectious Disease · COVID-19
8FDA Grants Emergency Use Authorization for Remdesivir in Severe COVID-19 Cases
InvestigateInfectious Disease · Antiviral
8FDA Authorizes Gohibic (vilobelimab) for COVID-19 Treatment
InvestigateInfectious Disease · COVID-19
8Phase III Trial of Afimkibart Shows Promise for Moderately to Severely Active Crohn's Disease
MonitorGastroenterology · Crohn's Disease
8Phase III Trial of Toripalimab and Lenvatinib for Advanced HCC Initiated
MonitorOncology · HCC
8Roche to present new Alzheimer’s data, including trontinemab and pTau217 blood test, at AAIC 2026
MonitorNeurology · Alzheimer's Disease
8Roche presents new Alzheimer’s data at AAIC 2026, highlighting trontinemab and blood tests
MonitorNeurology · Alzheimer's Disease
8KIBRA identified as a tumor suppressor in osteosarcoma via Wnt/β-catenin inhibition
InvestigateOncology · Osteosarcoma
8RBM15B/FOXM1/AURKA/TPX2 axis identified as key driver in endometrial cancer progression
InvestigateOncology · Endometrial Cancer
8SonoCloud-9 Enhances Carboplatin Delivery in Recurrent Glioblastoma Trial
MonitorOncology · Glioblastoma
8New Orthotopic Model Reveals CD8⁺ T Cell Dysfunction in Colorectal Cancer Immunotherapy
InvestigateOncology · Colorectal Cancer
8Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval
MonitorOncology · Immunomodulator
8FDA Approves Supplemental Application for Breztri Aerosphere
MonitorRespiratory · COPD
8FDA Grants Approval for Thalidomide ANDA213267 by NATCO
MonitorOncology · Immunomodulator
8Biogen's Felzartamab Study Targets Isolated Microvascular Inflammation in Kidney Transplant Patients
MonitorNephrology · Kidney Transplant
8FDA Accepts BLA for Anifrolumab by AstraZeneca
MonitorImmunology · Systemic Lupus Erythematosus
8Teva's Budesonide and Formoterol Fumarate Dihydrate Receives FDA Approval
MonitorRespiratory · Asthma/COPD
8Psilocybin Shows Promise in Preventing Relapse in Alcohol Use Disorder with Depression
MonitorAddiction · Psilocybin
8NCI Trials CD19/CD22 CAR T Cells for Refractory B Cell Malignancies in Young Patients
MonitorOncology · CAR T-cell Therapy
8Sandoz Receives FDA Approval for Enzalutamide ANDA216068
MonitorOncology · Androgen Receptor Inhibitor
8FDA Accepts NDA for IDVYNSO Containing Doravirine and Islatravir
MonitorInfectious Disease · HIV
8FDA Grants Priority Review for TZIELD (Teplizumab-MZWV) Supplement
MonitorAutoimmune · Type 1 Diabetes
8FDA Approves Supplemental Application for Cosentyx (Secukinumab)
MonitorImmunology · IL-17
8AstraZeneca's PT010 Study Targets Severe Asthma in Adults and Adolescents
MonitorRespiratory · Asthma
8BrainChild Bio Initiates CAR T Therapy Study for DIPG Patients
MonitorOncology · CAR T Cell Therapy
8Semaglutide (Wegovy) approved for metabolic-associated steatohepatitis treatment
MonitorHepatology · GLP-1 Agonist
8Study Reveals GES Variants Impact Resistance to Ceftazidime-Avibactam and Imipenem-Relebactam
MonitorInfectious Disease · Antibiotic Resistance
8Astellas initiates first-in-human trial of ASP2246 for post-stroke movement disorders
MonitorNeurology · Stroke Recovery
8Ruthenium-based metallodrug shows promise against cisplatin-resistant osteosarcoma
InvestigateOncology · Osteosarcoma
8FDA Investigates Neurologic Risks of General Anesthesia Linked to Genetic Variant
InvestigateNeurology · Anesthesia
8Abiomed Recalls Impella CP Sets Due to Low Purge Pressure Risk
InvestigateCardiology · Heart Pump
8Insulet Recalls Omnipod Pods Due to Insulin Leakage Risk
InvestigateDiabetes · Insulin Delivery
8FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC)
MonitorOncology · Monoclonal Antibody
8FDA Approves Supplemental Applications for TRELSTAR
MonitorOncology · Hormonal Therapy
8FDA Approves BLA761530 (LUMVOA) from Viridian Therapeutics
MonitorOncology · Monoclonal Antibody
8Phase III Trial of Afimkibart Shows Promise for Ulcerative Colitis
MonitorGastroenterology · Ulcerative Colitis
8FDA to Terminate Emergency Use Authorizations for COVID-19 Drugs
InvestigateInfectious Disease · COVID-19
8MHRA Approves Gemcitabine Delivery System for High-Risk Bladder Cancer
InvestigateOncology · Bladder Cancer
8Exosome-based delivery of Wedelolactone shows promise for sepsis-induced liver injury
InvestigateHepatology · Sepsis-induced liver injury
8RNA Modifications as Key Regulators in Cancer Translational Control and Therapeutic Strategies
InvestigateOncology · RNA Modifications
8Phase III Trial of Atezolizumab Post-Surgery for Stage I NSCLC Shows Promise
MonitorOncology · NSCLC
8FDA Approves Casgevy for Young Children with Sickle Cell Disease
MonitorHematology · Gene Therapy
8Hologic Recalls BioZorb Markers Due to Patient Complications Risk
InvestigateSurgery · Medical Devices
8FDA Approves Ferric Carboxymaltose ANDA212572 by Mylan Labs
MonitorHematology · Iron Deficiency Anemia
8FDA Approves Allogeneic T Cell Immunotherapy for Hematologic Malignancies
MonitorHematology · Immunotherapy
8FDA Approves TREGZI for Chronic GVHD in Blood Cancer Patients
InvestigateHematology · Immunotherapy
8LTβR as Novel Target for Cancer Immunotherapy: Mechanisms and Therapeutic Potential
InvestigateOncology · Immunotherapy
8Phase 3 Trial of Navenibart for Hereditary Angioedema Initiated by Astria Therapeutics
MonitorImmunology · Hereditary Angioedema
8Deep Learning Model Enhances Prognostic Prediction in Stage III Colon Cancer
InvestigateOncology · Colon Cancer
8Innovative Targeted Proteoform Degradation Enhances Precision Drug Design and Delivery
InvestigateOncology · Targeted Therapy
8Fenofibrate Trial Aims to Prevent Worsening of Diabetic Retinopathy
MonitorOphthalmology · Diabetic Retinopathy
8FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector
MonitorNeurology · RNA-targeted therapy
8FDA Approval Update for IBRANCE (Palbociclib) by Pfizer
MonitorOncology · CDK4/6 Inhibitor
8FDA Accepts Supplemental Application for KEYTRUDA QLEX
MonitorOncology · PD-1 Inhibitor
8FDA Approves Supplement for KEYTRUDA (pembrolizumab) by Merck
MonitorOncology · PD-1 Inhibitor
8FDA Accepts Supplement for Trodelvy (Sacituzumab Govitecan-Hziy)
MonitorOncology · Antibody-Drug Conjugate
8FDA Drug Trials Snapshot: YARTEMLEA Approved for TA-TMA
InvestigateHematology · Thrombotic Microangiopathy
8Phase I/II Trial of Lentiviral Gene Transfer for XSCID in Children Over Two Years
MonitorImmunology · Gene Therapy
8Cabozantinib plus Nivolumab Shows Promise in Advanced Non-Clear Cell RCC
MonitorOncology · Renal Cell Carcinoma
8Enhertu Secures EU Approval as First Tumour Agnostic HER2 Therapy
MonitorOncology · ADC
8FDA Grants Priority Review for Roche's Enspryng in Thyroid Eye Disease
MonitorOphthalmology · Autoimmune Disease
8FDA Grants Priority Review for Roche's Enspryng in Thyroid Eye Disease
MonitorOphthalmology · Thyroid Eye Disease
8Microneedle Delivery of Amphotericin B Shows Promise for American Cutaneous Leishmaniasis Treatment
MonitorInfectious Disease · Leishmaniasis
8FDA Approves Supplemental Application for AJOVY (Fremanezumab)
MonitorNeurology · Migraine
8FDA Approves Tioprinin for Treatment of Cystinosis
MonitorRare Diseases · Cystinosis
8FDA Orders Azurity Pharmaceuticals to Halt Distribution of Unapproved Compounding Kits
MonitorPharmaceuticals · Compounding
8Abiomed Issues Update on Automated Impella Controllers Due to Software Error
MonitorCardiology · Heart Pump Devices
8GE HealthCare Issues Correction for Infant Resuscitation Systems Due to Oxygen Concentration Risk
InvestigatePediatrics · Medical Devices
8FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc
MonitorPain Management · Opioid
8Roche Launches AXELIOS 1 Next-Generation Sequencing Platform
MonitorOncology · Genomics
8Roche Launches AXELIOS 1 Next-Generation Sequencing Platform
MonitorGenomics · Sequencing Technology
8Datroway recommended for EU approval as 1st-line treatment for TNBC
MonitorOncology · ADC
8MiNK Therapeutics Trials agenT-797 for Severe Pneumonia with AHRF
MonitorRespiratory · Severe Pneumonia
8Bristol-Myers Squibb Evaluates Pumitamig vs Pembrolizumab in NSCLC Trial
MonitorOncology · Non-Small Cell Lung Cancer
8BMS's Navlimetostat in NSCLC Trial vs. Placebo and Pembrolizumab
MonitorOncology · NSCLC
8Capivasertib plus Abiraterone Approved for PTEN-Deficient Prostate Cancer
InvestigateOncology · Prostate Cancer
8Mölnlycke Health Care Recalls Hibiwash Due to Microbial Contamination
InvestigateInfection Control · Antiseptic
8Bayer Plc Issues Class 3 Recall for Various Products Due to Impurity
InvestigateVarious · Pharmaceuticals
8TRIMELVax Vaccine Shows Neutrophils as Key Regulators of Antitumor Immunity
MonitorOncology · Cancer Vaccines
8SEC61G identified as a pan-cancer biomarker and potential therapeutic target
InvestigateOncology · Biomarker Discovery
8FDA Approves Supplemental Application for Trodelvy (Sacituzumab Govitecan-Hziy)
MonitorOncology · Antibody-Drug Conjugate
8FDA Grants Priority Review for TRYNGOLZA Autoinjector Submission
MonitorNeurology · RNA-targeted therapy
8FDA Approves Supplemental Application for IBRANCE (Palbociclib)
MonitorOncology · CDK4/6 Inhibitor
8AbbVie Initiates Phase 2b/3 Trial of Surabgene Lomparvovec for Diabetic Retinopathy
MonitorOphthalmology · Gene Therapy
8FDA Approves KEYTRUDA and Trodelvy Combination for First-Line TNBC Treatment
MonitorOncology · Triple-Negative Breast Cancer
8Lilly's Jaypirca recommended for EU approval in CLL across all therapy lines
InvestigateHematology · CLL
8Rising Bone Cancer Incidence Highlights Need for Improved Surgical Outcomes
InvestigateOncology · Bone Cancer
8FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)
MonitorNeurology · Multiple Sclerosis
8Axitinib and Survivin Vaccine Enhance PD-1 Therapy in Renal Carcinoma
InvestigateOncology · Renal Cell Carcinoma
8FDA Accepts Supplemental BLA for OCREVUS ZUNOVO by Genentech
MonitorNeurology · MS
8Phase 3 Study of Radiprodil in GRIN-related Neurodevelopmental Disorder Initiated
MonitorNeurology · GRIN-related Neurodevelopmental Disorder
8AstraZeneca's Elecoglipron Phase III Trials Target Obesity and T2DM
MonitorEndocrinology · Obesity
8Lilly's Obesity Medicines Accessible to Medicare Part D Patients via New Program
MonitorObesity · GLP-1 Agonists
8Study on Air Pollution's Impact on Cystic Fibrosis Severity in Hispanic Children
MonitorPulmonology · Cystic Fibrosis
8FDA approves sacituzumab govitecan-hziy for first-line triple-negative breast cancer
MonitorOncology · ADC
8FDA Approves Tryngolza for Reducing Acute Pancreatitis Risk in Severe Hypertriglyceridemia
InvestigateEndocrinology · Hypertriglyceridemia
8FDA Approves Palbociclib with Trastuzumab for HR-positive, HER2-positive Breast Cancer
MonitorOncology · Breast Cancer
8UK-wide ENDO1000 Study Aims to Advance Endometriosis Diagnosis and Treatment
MonitorWomen's Health · Endometriosis
8Immunostimulatory adjuvant reverses vaccine response decline in aged models
InvestigateImmunology · Vaccine Development
8Insights on HPV Vaccine Hesitancy to Enhance Global Vaccination Strategies
InvestigateOncology · HPV Vaccination
8miR-6833-3p Promotes Prostate Cancer Progression via NUMB-NOTCH Pathway Inhibition
InvestigateOncology · Prostate Cancer
8OTUD5-SLC7A11 Axis Identified as Novel Target in AML Progression
InvestigateOncology · Acute Myeloid Leukemia
8V116 shows safety and immunogenicity in high-risk children for pneumococcal disease
MonitorInfectious Disease · Pneumococcal Vaccination
8Cadonilimab Targets PD-1/PD-L1 Blockade-Refractory MSI-H/dMMR Colorectal Cancer
MonitorOncology · Colorectal Cancer
8Lilly acquires Centessa Pharmaceuticals to enhance sleep-wake disorder treatments
MonitorNeurology · Sleep-Wake Disorders
8European Commission Approves KEYTRUDA Plus Padcev for Cisplatin-Ineligible Bladder Cancer
MonitorOncology · Bladder Cancer
8FDA Approves Pfizer’s IBRANCE for HR+, HER2+ Metastatic Breast Cancer Maintenance
MonitorOncology · Breast Cancer
8FDA Approval for Oxycodone Hydrochloride by Novel Labs
InvestigatePain Management · Opioid
8JNJ-68284528 (cilta-cel) vs Standard Therapy in Multiple Myeloma Study Initiated
MonitorHematology · CAR-T
8Merck's Sacituzumab Tirumotecan Trial Targets High-Risk Breast Cancer
MonitorOncology · Breast Cancer
8Epcoritamab Shows Promise in High-risk Burkitt Lymphoma with DA-EPOCH-R in Phase II Trial
MonitorOncology · Burkitt Lymphoma
8Merck's KEYMAKER-U01 Study Explores Pembrolizumab in NSCLC with Chemotherapy
MonitorOncology · NSCLC
8Sterling Pharmaceuticals recalls KidNaps Melatonin due to stability issues
InvestigateNeurology · Sleep Disorders
8FDA Approves First Generic of Priftin (rifapentine) Tablets
MonitorInfectious Disease · Tuberculosis
8KIF18A Inhibitor Shows Promise Against Osteosarcoma Growth
InvestigateOncology · Osteosarcoma
8mRNA-LNP Vaccine TP0435 Shows Promise Against Syphilis in Animal Models
MonitorInfectious Disease · Syphilis
8Phase III Trial of Durvalumab Post-Surgery in Early-Stage NSCLC Shows Potential Benefit
MonitorOncology · Immunotherapy
8Accord Healthcare Recalls Carmustine Due to Out of Specification Test Result
InvestigateOncology · Chemotherapy
8Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna
MonitorOncology · Non-small Cell Lung Cancer
8Viatris Reports Quality Defect in Arixtra Pre-Filled Syringes
InvestigateCardiovascular · Anticoagulant
8Novel PSMA-targeted Imaging and SABR for Recurrent Prostate Cancer
MonitorOncology · Prostate Cancer
8FDA Approves Supplemental Application for Epcoritamab (EPKINLY)
MonitorOncology · Bispecific T-cell Engager
8FDA Grants Priority Review for UTEBZI (TEBIPENEM, PIVOXIL) by GlaxoSmithKline
MonitorInfectious Disease · Antibiotic
8FDA Grants Approval for Eltrombopag Olamine ANDA208815
MonitorHematology · Thrombocytopenia
8FDA Approves Baloxavir Marboxil for ANDA217449
MonitorInfectious Disease · Antiviral
8Chemoimmunotherapy Shows Promise in MSS Colorectal Cancer: Pooled Analysis Insights
MonitorOncology · Colorectal Cancer
8Phase II/III Trial of VIrR vs VDC/IE in Metastatic Ewing Sarcoma
MonitorOncology · Ewing Sarcoma
8Phase III Trial of Cemiplimab in NSCLC Post-Surgery Shows Promise for Disease-Free Survival
MonitorOncology · Immunotherapy
8Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study
MonitorGastroenterology · Ulcerative Colitis
8FDA Grants Approval for Macitentan ANDA211187 by Teva Pharmaceuticals
MonitorCardiology · Pulmonary Arterial Hypertension
8Phase Ⅲ Trial of Rilvegostomig in HER2-positive Gastric Cancer Initiated by AstraZeneca
MonitorOncology · HER2-positive Gastric Cancer
8Challenges in Rotavirus Vaccine Efficacy in Low- and Middle-Income Countries
InvestigateInfectious Disease · Vaccine
8FDA Grants Priority Review for Pfizer's Marstacimab (BLA761369)
MonitorHematology · Monoclonal Antibody
8New Non-Aqueous Rotavirus Vaccine Shows Promise for Ambient Shipping and Stability
InvestigateInfectious Disease · Vaccine
8Nipocalimab (Imaavy) Approved for Generalised Myasthenia Gravis Treatment
MonitorNeurology · Autoimmune Disorders
8Abiomed Issues Correction for Automated Impella Controllers Due to Safety Concerns
MonitorCardiology · Heart Pump
8Semaglutide tablet approved in the UK for weight loss
MonitorObesity · GLP-1
8Baxter's Volara System Faces Air Leak Issues Impacting Patient Therapy
MonitorRespiratory · Device
8FDA Approves Tzield for Pediatric Stage 3 Type I Diabetes
MonitorEndocrinology · Type I Diabetes
8FDA Approves First OTC Continuous Glucose Monitor for Children
MonitorDiabetes · Continuous Glucose Monitoring
8FDA approves capivasertib with abiraterone for PTEN-deficient prostate cancer
MonitorOncology · Prostate Cancer
8FDA approves belzutifan with pembrolizumab for renal cell carcinoma treatment
InvestigateOncology · Renal Cell Carcinoma
8Trial on Oxygen Saturation Targeting in Preterm Infants with Pulmonary Hypertension
MonitorPulmonology · Neonatal Care
8FTO/BCL6 Axis Identified as Therapeutic Target in Gastric Cancer Progression
InvestigateOncology · Gastric Cancer
8Targeted PEGylated PLGA Nanoparticles Enhance Hesperidin Delivery in Ovarian Cancer
MonitorOncology · Ovarian Cancer
8Progress on EBV Vaccine Development Critical for MS Prevention
InvestigateNeurology · Infectious Disease
8Ubiquitination signature identified in neuroendocrine prostate cancer with therapeutic implications
MonitorOncology · Prostate Cancer
8Dual-ligand cantharidin nanoparticles show promise for hepatocellular carcinoma treatment
MonitorOncology · Hepatocellular Carcinoma
8HPV-associated cancers impose significant burden on Peruvian men, highlighting need for vaccination and early diagnosis
InvestigateOncology · HPV-related Cancers
8FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals
MonitorImmunology · JAK Inhibitor
8FDA Grants Approval for Gallium Ga-68 Gozetotide (ANDA216410)
MonitorOncology · Radiopharmaceutical
8Targeting Macrophage Cytokine Circuit Offers New Strategy Against TNBC Metastasis
InvestigateOncology · Breast Cancer
8Study Optimizes Immunotherapy for Pancreatic Adenocarcinoma Treatment
MonitorOncology · Immunotherapy
8CircKPNA2 promotes colorectal cancer via RIN1-Ras pathway activation
InvestigateOncology · Colorectal Cancer
8Lactobacillus reuteri promotes ferroptosis resistance in esophageal cancer via STAT3 lactylation
InvestigateOncology · Esophageal Squamous Cell Carcinoma
8Novel KRAS(G12V)-targeting peptide shows potent activity against colorectal cancer cells
InvestigateOncology · Colorectal Cancer
8FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement
MonitorHematology · Monoclonal Antibody
8NCI's MATCH Trial Evaluates Genetic Testing for Targeted Therapy in Advanced Cancers
MonitorOncology · Targeted Therapy
8FDA Grants Approval for Thalidomide ANDA213267 by NATCO
MonitorOncology · Antineoplastic
8Novel Oral Nanoemulsion Targets Hepatic Stellate Cells in Liver Fibrosis Treatment
InvestigateHepatology · Liver Fibrosis
8Ravulizumab Shows Promise in Reducing Delayed Graft Function in Kidney Transplant Patients
MonitorNephrology · Monoclonal Antibody
8Limited FDA-approved Antihypertensive Therapies for Pediatric Patients Highlighted
InvestigateCardiology · Antihypertensive
8HPV Vaccination Linked to Decline in High-Grade CIN Consultations in Brazil
InvestigateOncology · Cervical Cancer
8Shikonin Induces Ferroptosis in DLBCL via lncRNA ADPGK-AS1 Downregulation
InvestigateOncology · Diffuse Large B-Cell Lymphoma
8Draeger Issues Correction for A350 and A350XL Anesthesia Machines Due to Ventilator Failure Risk
MonitorAnesthesia · Medical Devices
8Phase II Trial of Lutetium Lu 177 Dotatate in Advanced Bronchial Neuroendocrine Tumors
MonitorOncology · Radioconjugate
8MITF-Driven Plasticity in Melanoma: Key to Overcoming Therapy Resistance
InvestigateOncology · Melanoma
8FCGR2B Targeting Enhances Anti-Tumor Activity of Macrophages in Melanoma
InvestigateOncology · Immunotherapy
8RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization
InvestigateOncology · Multiple Myeloma
8MAGED4 promotes HCC progression via JAK2/STAT3 pathway activation
InvestigateOncology · Hepatocellular Carcinoma
8FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose
InvestigateNeurology · Opioid Overdose
8FDA Accepts Supplement Application for YERVOY (ipilimumab)
MonitorOncology · Immune Checkpoint Inhibitor
8FDA Grants Priority Review for TZIELD (Teplizumab) Supplement
MonitorImmunology · Type 1 Diabetes
8FDA Grants Priority Review for Welireg Supplement from Merck
MonitorOncology · Small Molecule
8Guidance on Distinction Between Angioedema Types for ACE-Inhibitor Users
MonitorCardiology · ACE Inhibitors
8Gut Microbial Markers Linked to Immunotherapy Response in Melanoma Identified in Cross-Cohort Study
MonitorOncology · Melanoma
8FDA Approves First Generic of Xofluza for Influenza Treatment
InvestigateInfectious Disease · Influenza
8Advancements in NK Cell-Based Immunotherapy for Cancer Treatment
InvestigateOncology · Immunotherapy
8ULK1 Modulation Shows Promise in Cancer Therapy with DCC-3116 in Clinical Evaluation
MonitorOncology · ULK1 Inhibition
8FDA Approves First Oral Carbapenem for Complicated UTIs
MonitorInfectious Disease · Antibiotic
8FDA Launches National Priority Voucher Program to Accelerate Drug Review Times
InvestigateGeneral · Drug Development
8Phase II Trial of Venetoclax and HMA in FLT3 Mutated AML Patients
MonitorOncology · Acute Myeloid Leukemia
8Tislelizumab and Zeprumetostat Show Promise in NK/T-Cell Lymphoma Phase Ib/II Trial
MonitorOncology · NK/T-Cell Lymphoma
8Lilly to present positive Phase 3 results for pirtobrutinib in CLL at EHA 2026
MonitorHematology · CLL
8Abiomed and Oscor Warn of Catheter Introducer Leakage Risk
MonitorCardiovascular · Medical Devices
8Medline Industries Expands Catheter Recall Due to Infection Risk
MonitorCardiology · Catheters
8Amgen's Xaluritamig Plus Abiraterone Trial Targets Metastatic Prostate Cancer
MonitorOncology · Prostate Cancer
8Phase II Trial of ILDR Plus Immunochemotherapy in Borderline Resectable Esophageal Cancer
MonitorOncology · Esophageal Squamous Cell Carcinoma
8Phase III Trial of Early Treatment in High-Risk CLL/SLL Shows Promise
MonitorOncology · CLL/SLL
8FDA Approves CAPVAXIVE for At-Risk Children and Adolescents
MonitorInfectious Disease · Pneumococcal Vaccine
8Study on Frailty in Young Adult Survivors of Childhood Cancer Highlights Long-term Health Risks
InvestigateOncology · Survivorship
8FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application
MonitorOncology · PD-1 Inhibitor
8FDA Grants Priority Review for Welireg Supplement NDA215383
MonitorOncology · Small Molecule
8Digital Management Improves Outcomes in Early Cardiogenic Shock Patients
MonitorCardiology · Cardiogenic Shock
8ComboMATCH Trial Targets Genetic Mutations in Advanced Solid Tumors
MonitorOncology · Solid Tumors
8Phase III Trial of Nivolumab Post-Surgery in Non-Small Cell Lung Cancer
MonitorOncology · Immunotherapy
8Phase III Trial of Atezolizumab with Chemotherapy for Metastatic Colorectal Cancer Initiated
MonitorOncology · Colorectal Cancer
8Trial Comparing Radiotherapy with Dual Immunotherapy in Locally Advanced Rectal Cancer
MonitorOncology · Rectal Cancer
8Phase III Trial of Pembrolizumab Plus Doxorubicin in Aggressive Sarcomas
MonitorOncology · Sarcoma
8Sintilimab and Ipilimumab Show Promise in First-line Therapy for Advanced Biliary Tract Cancers
InvestigateOncology · Biliary Tract Cancer
8FDA Accepts Application for BAXFENDY (BAXDROSTAT) from AstraZeneca
MonitorEndocrinology · Hypertension
8Cardiff Oncology and Pfizer assess onvansertib in metastatic colorectal cancer trial
MonitorOncology · Colorectal Cancer
8FDA Proposes Exclusion of Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List
InvestigateEndocrinology · GLP-1 Agonists
8NORM-HF Study to Evaluate FIRE1 NORM™ System in Heart Failure Management
MonitorCardiology · Heart Failure
8FDA Approves Supplement for INQOVI (NDA 212576) by Taiho Oncology
MonitorOncology · Antineoplastic
8STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism
InvestigateOncology · Breast Cancer
8OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients
MonitorInfectious Disease · COVID-19
8Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis
InvestigateOncology · Ovarian Cancer
8Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma
InvestigateOncology · Melanoma
8Novel Pra-peptide hydrogel shows promise for treating ocular inflammation
InvestigateOphthalmology · Ocular Inflammation
8Gut Microbiota Impairs Flutamide Efficacy in Prostate Cancer Treatment
InvestigateOncology · Prostate Cancer
8Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma
MonitorOncology · Pancreatic Adenocarcinoma
8E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice
InvestigateOncology · HPV-related cancers
8Phase III Trial of Pembrolizumab with Chemotherapy in Non-small Cell Lung Cancer
MonitorOncology · Immunotherapy
8Phase 3 Study of L606 in Patients with PH-ILD Shows Safety and Efficacy Potential
MonitorPulmonology · Pulmonary Hypertension
8Phase 3 Trial of Orelabrutinib in Secondary Progressive MS Underway
MonitorNeurology · Multiple Sclerosis
8Phase III Trial of Herceptin Hylecta or Phesgo with Chemotherapy for HER2 Positive Endometrial Cancer
MonitorOncology · HER2 Positive Endometrial Cancer
8Phase III Trial of MEDI5752 in Unresectable Pleural Mesothelioma Launched
MonitorOncology · Mesothelioma
8Phase III Trial of Giredestrant vs Endocrine Therapy in ER+ HER2- Early Breast Cancer
MonitorOncology · Breast Cancer
8Ifinatamab Deruxtecan Receives Priority Review for ES-SCLC in the U.S.
MonitorOncology · Small Cell Lung Cancer
8Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated
MonitorOncology · NSCLC
8Phase III Trial Evaluates Cemiplimab with Surgery for Advanced Skin Cancer
MonitorOncology · Skin Cancer
8Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer
MonitorOncology · NSCLC
8Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough
MonitorRespiratory · Chronic Cough
8ACADIA Pharmaceuticals initiates ACP-204 trials for Alzheimer's Disease Psychosis
MonitorNeurology · Alzheimer's Disease
8Phase III Trial of SYHA1813 Shows Promise for High-Grade Meningiomas
MonitorOncology · CNS Tumors
8Phase III Trial of Dinutuximab in High-Risk Neuroblastoma Shows Promise
MonitorOncology · Neuroblastoma
8Pfizer's Phase 3 Study of Tofacitinib in Pediatric Ulcerative Colitis Underway
MonitorGastroenterology · Ulcerative Colitis
8Merck's Acquisition of Terns Pharmaceuticals Advances as HSR Waiting Period Expires
MonitorOncology · Small Molecule
8FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment
InvestigateOncology · Bladder Cancer
8FDA Approves Merck’s IDVYNSO for Virologically Suppressed HIV-1 Patients
MonitorInfectious Disease · HIV
8Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC
InvestigateOncology · Renal Cell Carcinoma
8Roche Reports Strong Q1 2026 Sales Growth Driven by Innovative Medicines and Diagnostics
MonitorOncology · Diagnostics and Multiple Sclerosis · BTK Inhibitor
8mRNA-1083 Shows Durable Immune Response and Safety in Adults ≥50 Years
MonitorInfectious Disease · Vaccine
8Phase III Trial of Durvalumab with Chemotherapy in Stage II-III Breast Cancer
MonitorOncology · Immunotherapy
8Calderasib and Pembrolizumab Study in KRAS G12C NSCLC Shows Promising Efficacy
MonitorOncology · NSCLC
8NeoAdjuvant Therapy Trial for TNBC: Sacituzumab Govitecan + Pembrolizumab
MonitorOncology · Triple-Negative Breast Cancer
8Overview of Antibody-Drug Conjugates in Cancer Therapy and Clinical Development
InvestigateOncology · ADC
8Merck Acquires Terns Pharmaceuticals, Enhancing Oncology Pipeline with TERN-701
MonitorOncology · BCR::ABL1 Inhibition
8Merck Receives FDA Approval for IDVYNSO, Expands Oncology Pipeline and Animal Health Sales
MonitorInfectious Disease · HIV-1
8Roche Presents New Data on Vabysmo and Susvimo at ARVO 2026
MonitorOphthalmology · Retinal Diseases
8Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients
InvestigateOncology · Multiple Myeloma
8FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma
InvestigateOncology · NRG1 Fusion-Positive Cholangiocarcinoma
8FDA Approves Tzield for Pediatric Patients with Stage 3 Type 1 Diabetes
InvestigateEndocrinology · Type 1 Diabetes
8CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial
MonitorOncology · Melanoma
8Ashwagen® shows efficacy in managing stress and anxiety in hypertensive patients
InvestigatePsychiatry · Stress and Anxiety
8FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns
InvestigateOncology · Breast Cancer
8Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate
MonitorCardiovascular · PCSK9 Inhibition
8Roche to Acquire PathAI for $750M to Enhance AI-Driven Diagnostics
MonitorOncology · Digital Pathology
8Roche to Acquire PathAI for $750M to Enhance AI-Driven Diagnostics
InvestigateOncology · Digital Pathology
8CVS Caremark to cover Foundayo and Zepbound, enhancing access for obesity treatment
MonitorObesity · Pharmacotherapy
8Lilly expands infectious disease portfolio with three strategic acquisitions
MonitorInfectious Disease · Viral and Bacterial Pathogens
8Lilly's Foundayo Shows Significant Weight Loss in Menopausal Women
MonitorEndocrinology · GLP-1
8FDA approves Lilly's EBGLYSS® for atopic dermatitis with unique dosing regimen
MonitorDermatology · Atopic Dermatitis
8NextCOVE trial shows mRNA-1283 vaccine elicits higher nAb responses than mRNA-1273
InvestigateInfectious Disease · COVID-19
8FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC
InvestigateOncology · KRAS G12C Inhibitor
8Lilly's VERVE-102 Shows Significant LDL-C Reduction in Phase 1b Trial
InvestigateCardiovascular · Gene Editing
8Merck Reports Promising Long-Term Data for KEYTRUDA and Intismeran in Oncology at ASCO 2026
InvestigateOncology · Immunotherapy
8Saphnelo Self-Administration Approved in the US for SLE Treatment
MonitorImmunology · Systemic Lupus Erythematosus
8Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Detection
MonitorNeurology · Alzheimer's Disease
8European Commission Approves Pfizer’s HYMPAVZI for Hemophilia A and B Treatment
MonitorHematology · Hemophilia A/B
8Roche Launches Liver Disease Panel to Enhance Chronic Liver Disease Management
MonitorHepatology · Chronic Liver Disease
8Lilly's Foundayo shows superior A1C reduction and weight loss in pivotal diabetes trials
MonitorDiabetes · GLP-1
8Truqap approved in US for PTEN-deficient metastatic prostate cancer
InvestigateOncology · Prostate Cancer
85-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%
InvestigateOncology · Melanoma
8Lilly's Retevmo shows 83% reduction in disease recurrence for early-stage RET fusion-positive lung cancer
InvestigateOncology · RET fusion-positive lung cancer
8Lilly's Foundayo shows superior results in Phase 3 trial for type 2 diabetes
MonitorEndocrinology · Type 2 Diabetes
8Imfinzi Gains US Approval for Early Bladder Cancer with BCG Combination
InvestigateOncology · Immunotherapy
8Enhertu Gains FDA Approval for Two New HER2+ Early Breast Cancer Indications
InvestigateOncology · HER2-positive Breast Cancer
8Foundayo shows significant weight reduction in older adults with obesity in new analysis
MonitorObesity · Oral GLP-1 receptor agonist
8Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026
MonitorOncology · NSCLC
8Lilly's retatrutide shows significant weight loss in Phase 3 obesity trial
MonitorObesity · Triple Agonist
8Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir
InvestigateInfectious Disease · HIV
8Imfinzi + EV shows significant survival benefits in muscle-invasive bladder cancer
InvestigateOncology · Bladder Cancer
8Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide
InvestigateObesity · GLP-1/GIP Receptor Agonist and Amylin Analog
8Roche Advances Obesity Portfolio with Promising Phase II Data for Enicepatide and Petrelintide
InvestigateObesity · GLP-1/GIP Receptor Agonist and Amylin Analog
8Camizestrant Recommended for 1st-Line ER-Positive Breast Cancer in EU
MonitorOncology · ER-positive Breast Cancer
8Merck's KEYTRUDA Plus Padcev Receives Positive EU CHMP Opinion for Muscle-Invasive Bladder Cancer
MonitorOncology · Bladder Cancer
8Merck's Sacituzumab Tirumotecan Shows OS and PFS Improvement in Endometrial Cancer Phase 3 Trial
InvestigateOncology · ADC
8Roche and Nurix Collaborate on BTK Degrader Bexobrutideg for B-cell Malignancies
InvestigateOncology · B-cell Malignancies
8Roche and Nurix Collaborate on BTK Degrader Bexobrutideg for B-cell Malignancies
InvestigateHematology · BTK Degrader
8Tozorakimab Shows Positive Phase III Results in COPD, Reducing Exacerbations
MonitorRespiratory · COPD
8Ultomiris meets primary endpoint in Phase III trial for IgAN
MonitorNephrology · Complement Inhibition
8Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
InvestigateOncology · NSCLC
8Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
InvestigateInfectious Disease · Pneumococcal Vaccine
8Pfizer and Innovent Collaborate on 12 Early-Stage Oncology Programs
MonitorOncology · ADC
8Pfizer's Berobenatide Shows Promising Phase 2b Results for Monthly Dosing in Obesity Management
MonitorObesity · GLP-1 Receptor Agonist
8Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer
MonitorOncology · Breast Cancer
8Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer
MonitorOncology · Breast Cancer
8TALZENNA Plus XTANDI Shows 52% rPFS Improvement in Metastatic Prostate Cancer
MonitorOncology · Prostate Cancer
8Pfizer’s BRAFTOVI Regimen Nearly Doubles Progression-Free Survival in mCRC
MonitorOncology · Colorectal Cancer
8Nanomaterial-based vaccines show promise for improved rotavirus protection
InvestigateInfectious Disease · Vaccine
8Novel CD2-targeted bispecific antibody enhances T cell engagers for solid tumors
MonitorOncology · Bispecific Antibodies
8Phase III Trial of TR115 vs Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
MonitorOncology · EZH2 Inhibitor
8Lilly's Jaypirca shows 45% reduction in disease progression risk in CLL/SLL
InvestigateHematology · CLL/SLL
8Lilly presents promising Phase 1 data for first-in-class type II JAK2 inhibitor in myelofibrosis
InvestigateHematology · Myelofibrosis
8Rivaroxaban Trial for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients
MonitorCardiology · Anticoagulation
8FDA Approves KEYTRUDA Combinations for Adjuvant Treatment in Clear Cell RCC
MonitorOncology · Renal Cell Carcinoma
8Roche's VENTANA PTEN Assay Receives FDA Approval for Prostate Cancer Companion Diagnostic
MonitorOncology · Prostate Cancer
8Phase 3 Study of CU-20101 Shows Promise for Glabellar Lines Compared to Botox
MonitorDermatology · Aesthetic Medicine
8FDA grants Priority Review for Roche’s Tecentriq in stage III colon cancer
MonitorOncology · Immunotherapy
8FDA Clears Bridge Device for Opioid Use Disorder Treatment; Efficacy Under Evaluation
MonitorAddiction Medicine · Opioid Use Disorder
8Pridopidine Phase 3 Trial Initiated for ALS Efficacy and Safety Evaluation
MonitorNeurology · ALS
8LIPUS and microbubbles enhance amphotericin B delivery for cryptococcal meningitis therapy
InvestigateInfectious Disease · Fungal Infections
8FDA Approves Pfizer’s HYMPAVZI for Expanded Hemophilia A and B Indications
InvestigateHematology · Hemophilia A/B
8Lilly's Retatrutide Shows Significant Weight Loss and Pain Reduction in TRIUMPH-1 Trial
MonitorObesity · Triple Agonist
High impact signals
Score 6–7 — strategic review recommended
Monitor
Score ≤ 5 — track for context
5Comparative Study of SPSIPB vs Thoracic Paravertebral Block for Opioid Reduction
MonitorPain Management · Anesthesia
5Pilot Study on Geniculate Artery Embolization for Knee Osteoarthritis Initiated
MonitorMusculoskeletal · Osteoarthritis
5Trial on Pulmonary Artery Catheters in Cardiac Surgery Aims to Compare Recovery Outcomes
Company Intelligence
Shareable intelligence pages for leading pharma organizations
Regunera
Precedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitiva
Competitors · threats
Loading competitive findings…
View full competitive analysisPrognexa
Portfolio · strategy intelligence
Portfolio outlook
Strategic Implications of Lipfendra's Approval as First Oral PCSK9 Inhibitor
Pharma companies with injectable PCSK9 inhibitors may need to reassess their market strategies and consider the impact of this oral option on patient adherence and market share. The strongest clinical anchor is Accelerated High-Dose tDCS for Depression (ClinicalTrials.gov), sub-indication match (ild). In ild, 2 regulatory and 2 competitive items passed relevance filtering for Lipfendra.
Bullish64% confidence
Resmetirom Approval Signals Strategic Shifts in MASH Market Dynamics
Portfolio teams should assess the strategic fit of Resmetirom within their offerings and consider potential partnerships or competitive responses. The strongest clinical anchor is Trial of Treatments for COVID-19 in Hospitalized Adults (ClinicalTrials.gov), moderate corpus alignment. In Hepatology · Metabolic Dysfunction-Associated Steatohepatitis, 6 regulatory and 2 competitive items passed relevance filtering for competitors in hepatology.
Syntherx
Scenario analysis · forward-looking intelligence
Scenario cards
Strategic Implications of Lipfendra's Approval as First Oral PCSK9 Inhibitor
Strategic Implications of Lipfendra's Approval as First Oral PCSK9 Inhibitor
Base CaseBase
Regulatory risk is concentrated around FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease (FDA). Sub-indication match (ild); Regulatory pathway relevance (approval).
Upside CaseUpside
The introduction of Lipfendra could disrupt market share for injectable PCSK9 inhibitors, affecting revenue streams for companies currently offering these therapies. Companies may need to adapt their marketing and pricing strategies to remain competitive.